Expert: Tumor necrosis factor alpha inhibitor that binds and neutralizes TNF-α, reducing inflammatory signaling. Cimzia is pegylated for extended half-life.

Everyday: Blocks TNF, a protein that causes inflammation in autoimmune diseases.

Targets: ["TNF"]

TNF-alpha inhibitor. Legacy standard of care for psoriasis and many autoimmune diseases. PASI 90 ~45% Wk16. Beaten by every newer class in H2H trials. Peak revenue $20.7B (2021) — highest-selling drug in history. US biosimilars launched Jan 2023 (10 approved). Revenue declining steeply: $14.4B (2023) → $8.99B (2024) → $4.54B (2025). In psoriasis, now rarely used first-line given IL-23 and IL-17 class superiority. Still used in other indications (RA, IBD) where biosimilar switching is slower.

{"keyRisks":[{"category":"Infections","description":"Serious infections including TB, invasive fungal infections"},{"category":"Malignancy","description":"Lymphoma and other malignancies, especially in children/adolescents"},{"category":"HBV Reactivation","description":"Hepatitis B virus reactivation"}],"monitoring":["TB screening","HBV screening"],"labelSource":"FDA PI 2024","classWarnings":["TNF inhibitor class warning"],"hasBoxedWarning":true,"boxedWarningText":"SERIOUS INFECTIONS AND MALIGNANCY","contraindications":["Active serious infections"],"boxedWarningCategories":["Infections","Malignancy"]}